Targeting DNA methylation for epigenetic therapy.

[1]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[2]  Alain L. Gervais,et al.  Reconciling the positive and negative roles of histone H2A.Z in gene transcription , 2010, Epigenetics.

[3]  D. Zilberman,et al.  Genome-Wide Evolutionary Analysis of Eukaryotic DNA Methylation , 2010, Science.

[4]  R. Ganetzky,et al.  Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Peter A. Jones,et al.  S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth , 2010, Molecular Cancer Therapeutics.

[6]  C. Bloomfield,et al.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine , 2010, Proceedings of the National Academy of Sciences.

[7]  P. Farnham,et al.  5-azacytidine treatment reorganizes genomic histone modification patterns , 2010, Epigenetics.

[8]  G. Mufti,et al.  Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C , 2010, British journal of haematology.

[9]  P. Musto,et al.  Azacitidine for the treatment of lower risk myelodysplastic syndromes , 2010, Cancer.

[10]  Clifford A. Meyer,et al.  Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.

[11]  E. Estey,et al.  Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept , 2010, British journal of haematology.

[12]  R. Schüle,et al.  Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. , 2010, Carcinogenesis.

[13]  Helen Brady,et al.  A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines , 2010, PloS one.

[14]  Takayoshi Suzuki,et al.  Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[15]  D. Berry,et al.  Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes , 2010, Leukemia & lymphoma.

[16]  Michele D. Sobolewski,et al.  Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells , 2010, Breast Cancer Research and Treatment.

[17]  D. Steensma.  Decitabine treatment of patients with higher-risk myelodysplastic syndromes. , 2009, Leukemia research.

[18]  V. Santini.  Azacitidine in lower-risk myelodysplastic syndromes. , 2009, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[19]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[20]  Peter A. Jones,et al.  Rethinking how DNA methylation patterns are maintained , 2009, Nature Reviews Genetics.

[21]  L. Marton,et al.  Polyamine analogues targeting epigenetic gene regulation. , 2009, Essays in biochemistry.

[22]  Lucy Skrabanek,et al.  MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. , 2009, Blood.

[23]  J. Herman,et al.  A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors , 2009, Clinical Cancer Research.

[24]  Chris A. Nasrallah,et al.  Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. , 2009, Blood.

[25]  R. Vij,et al.  A phase II study of 5‐day intravenous azacitidine in patients with myelodysplastic syndromes , 2009, American journal of hematology.

[26]  P. Marks,et al.  Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia , 2009, American journal of hematology.

[27]  H. Kantarjian,et al.  Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Gobbi,et al.  Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes , 2009, Clinical Cancer Research.

[29]  Kairong Cui,et al.  H3.3/H2A.Z double variant-containing nucleosomes mark ‘nucleosome-free regions’ of active promoters and other regulatory regions in the human genome , 2009, Nature Genetics.

[30]  Peter A. Jones,et al.  Selective Anchoring of DNA Methyltransferases 3A and 3B to Nucleosomes Containing Methylated DNA , 2009, Molecular and Cellular Biology.

[31]  Luc Gaudreau,et al.  Histone H2A.Z is essential for estrogen receptor signaling. , 2009, Genes & development.

[32]  C. Bloomfield,et al.  MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. , 2009, Blood.

[33]  J. Issa,et al.  Targeting DNA Methylation , 2009, Clinical Cancer Research.

[34]  I. Wistuba,et al.  Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas , 2009, Clinical Cancer Research.

[35]  K. Ghoshal,et al.  A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. , 2009, Cancer research.

[36]  J. Medina-Franco,et al.  Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase 1 , 2009, ChemMedChem.

[37]  H. Kantarjian,et al.  Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia , 2009, Cancer.

[38]  H. Cedar,et al.  Linking DNA methylation and histone modification: patterns and paradigms , 2009, Nature Reviews Genetics.

[39]  Laura Vidal,et al.  Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[40]  J. Hainsworth,et al.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  I. Pogribny,et al.  DNA hypomethylation in the origin and pathogenesis of human diseases , 2009, Cellular and Molecular Life Sciences.

[42]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[43]  R. Versteeg,et al.  Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. , 2009, Cancer research.

[44]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[45]  P. Milburn,et al.  Dynamic Histone Variant Exchange Accompanies Gene Induction in T Cells , 2009, Molecular and Cellular Biology.

[46]  J. Issa,et al.  Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome , 2009, Bone Marrow Transplantation.

[47]  J. Issa,et al.  Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. , 2009, Blood.

[48]  D. Keppler,et al.  Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation , 2009, Molecular Cancer Therapeutics.

[49]  C. Plass,et al.  The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells , 2009, Leukemia.

[50]  A. Oza,et al.  Phase I Study of MG 98 , an OligonucleotideAntisense Inhibitor of Human DNAMethyltransferase 1 , Given as a 7-Day Infusion in Patients with Advanced SolidTumors , 2009 .

[51]  Peter A. Jones,et al.  The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. , 2009, Cancer research.

[52]  K. Götze,et al.  A limited number of 5-azacitidine cycles can be effective treatment in MDS , 2009, Annals of Hematology.

[53]  Yinhong Song,et al.  Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression , 2009, Cancer Chemotherapy and Pharmacology.

[54]  M. Bernstein,et al.  Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine , 2009, Cancer Chemotherapy and Pharmacology.

[55]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[56]  M. Lübbert,et al.  Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups , 2008 .

[57]  Jun S. Song,et al.  Chromatin structure analyses identify miRNA promoters , 2008 .

[58]  R. Young,et al.  H2AZ Is Enriched at Polycomb Complex Target Genes in ES Cells and Is Necessary for Lineage Commitment , 2008, Cell.

[59]  S. Henikoff,et al.  Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks , 2008, Nature.

[60]  D. Schübeler,et al.  DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity , 2008, The EMBO journal.

[61]  H. Kimura,et al.  G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription , 2008, The EMBO journal.

[62]  Yusuke Nakamura,et al.  Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism , 2008, Nature.

[63]  A. Raza,et al.  Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia , 2008, Cancer.

[64]  Razelle Kurzrock,et al.  Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers , 2008, Clinical Cancer Research.

[65]  S. Ropero,et al.  A microRNA DNA methylation signature for human cancer metastasis , 2008, Proceedings of the National Academy of Sciences.

[66]  Gangning Liang,et al.  Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line , 2008, Proceedings of the National Academy of Sciences.

[67]  P. Laird,et al.  2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. , 2008, Cancer letters.

[68]  Michael Q. Zhang,et al.  Combinatorial patterns of histone acetylations and methylations in the human genome , 2008, Nature Genetics.

[69]  F. Lyko,et al.  Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.

[70]  D. Gold,et al.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation , 2008, Nature Genetics.

[71]  M. Toyota,et al.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. , 2008, Cancer research.

[72]  A. Bird,et al.  DNA methylation landscapes: provocative insights from epigenomics , 2008, Nature Reviews Genetics.

[73]  J. Byrd,et al.  A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia , 2008, Clinical Cancer Research.

[74]  E. Vokes,et al.  Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904 , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  Peter A. Jones,et al.  Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice , 2008, Cancer Prevention Research.

[76]  Dustin E. Schones,et al.  Genome-wide approaches to studying chromatin modifications , 2008, Nature Reviews Genetics.

[77]  Jordanka Zlatanova,et al.  H2A.Z: view from the top. , 2008, Structure.

[78]  Xueyan Zhong,et al.  High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer , 2008, Proceedings of the National Academy of Sciences.

[79]  James H. Doroshow,et al.  Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) , 2008, Cancer Chemotherapy and Pharmacology.

[80]  Jacqueline A. Hall,et al.  Identification of Novel High-Frequency DNA Methylation Changes in Breast Cancer , 2007, PloS one.

[81]  R. Amato.  Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. , 2007, Clinical genitourinary cancer.

[82]  Peter A. Jones,et al.  Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. , 2007, Cancer cell.

[83]  Andreas Schätzlein,et al.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[85]  S. Jacobsen,et al.  UHRF1 Plays a Role in Maintaining DNA Methylation in Mammalian Cells , 2007, Science.

[86]  Xiaodong Cheng,et al.  Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation , 2007, Nature.

[87]  M. Grever,et al.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. Griffith,et al.  5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. , 2007, Cancer research.

[89]  C. Allis,et al.  DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA , 2007, Nature.

[90]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[91]  R. Young,et al.  A Chromatin Landmark and Transcription Initiation at Most Promoters in Human Cells , 2007, Cell.

[92]  S. Berger.  The complex language of chromatin regulation during transcription , 2007, Nature.

[93]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[94]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[95]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[96]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[97]  J. Issa,et al.  Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia , 2007, Cancer.

[98]  Nathaniel D. Heintzman,et al.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome , 2007, Nature Genetics.

[99]  Bing Li,et al.  The Role of Chromatin during Transcription , 2007, Cell.

[100]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[101]  Daniel Chourrout,et al.  Genome Regulation by Polycomb and Trithorax Proteins , 2007, Cell.

[102]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[103]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[104]  C. Hsieh,et al.  DNA Methylation Dictates Histone H3K4 Methylation , 2007, Molecular and Cellular Biology.

[105]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[106]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[107]  Julie L Eiseman,et al.  Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice , 2006, Clinical Cancer Research.

[108]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[109]  Ming Zhao,et al.  Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.

[110]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  A. Dueñas-González,et al.  Journal of Translational Medicine Global Dna Hypermethylation-associated Cancer Chemotherapy Resistance and Its Reversion with the Demethylating Agent Hydralazine , 2022 .

[112]  Kelly B. Moran,et al.  Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[113]  Peter A. Jones,et al.  Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. , 2006, Cancer cell.

[114]  J. Issa,et al.  DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. , 2006, Cancer research.

[115]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[116]  H. Stopper,et al.  Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. , 2006, Cancer research.

[117]  E. Eisenhauer,et al.  Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study , 2006, Investigational New Drugs.

[118]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[119]  Luyang Sun,et al.  Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis , 2005, Nature.

[120]  Peter A. Jones,et al.  Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine , 2005, Molecular Cancer Therapeutics.

[121]  K. Ghoshal,et al.  5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal , 2005, Molecular and Cellular Biology.

[122]  Suk Woo Nam,et al.  Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[123]  P. Jones,et al.  Zebularine: a new drug for epigenetic therapy. , 2004, Biochemical Society transactions.

[124]  Peter A. Jones,et al.  Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[125]  Hing Y Leung,et al.  Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.

[126]  Yong Wang,et al.  An evaluation of new criteria for CpG islands in the human genome as gene markers , 2004, Bioinform..

[127]  Satoshi Tanaka,et al.  Epigenetic Control of Mouse Oct-4 Gene Expression in Embryonic Stem Cells and Trophoblast Stem Cells* , 2004, Journal of Biological Chemistry.

[128]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[129]  Peter A. Jones,et al.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[130]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[131]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  Daiya Takai,et al.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[134]  T. Bestor,et al.  Dnmt3L and the Establishment of Maternal Genomic Imprints , 2001, Science.

[135]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[136]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[137]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[138]  P. Jones,et al.  DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. , 1986, The Journal of biological chemistry.

[139]  G. Reaman,et al.  Phase II study of 5‐azacytidine in sarcomas of bone , 1982, American journal of clinical oncology.

[140]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[141]  Peter A. Jones,et al.  Multiple new phenotypes induced in 10T 1 2 and 3T3 cells treated with 5-azacytidine , 1979, Cell.

[142]  J. Veselý,et al.  5-Azacytidine: Mechanism of action and biological effects in mammalian cells , 1978 .

[143]  A. Bartolucci,et al.  Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study. , 1977, Cancer treatment reports.

[144]  L H Li,et al.  Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. , 1970, Cancer research.